Home
Storia in 2 fonti
Novo Nordisk CEO addresses U.S. headwinds after guidance shock
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.
- ·
cnbc.com
Novo Nordisk tumbles 11% after forecasting sales declines this year
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
- ·
Novo Nordisk CEO addresses U.S. headwinds after guidance shock
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.
- ·
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.
- ·
theguardian.com
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition